Placebo to Tolterodine

DRUG2 trials

Sponsors

Astellas Pharma Inc

Conditions

Urinary Bladder, Overactive

Phase 3

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

CompletedNCT00689104

Astellas Pharma IncUrinary Bladder, Overactive

Start: 2008-04-28End: 2009-03-24Updated: 2024-11-20

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

CompletedNCT00688688

Astellas Pharma IncUrinary Bladder, Overactive

Start: 2008-04-25End: 2010-05-06Updated: 2024-11-20

Related Papers

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.

2013-11-1920 citations

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.

2013-09-1842 citations

Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.

2013-07-124 citations

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

2012-11-06310 citations

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

2012-11-06233 citations